Histopathology of BRCA1- and BRCA2-associated breast cancer

Critical Reviews in Oncology/Hematology

Volumn 59, Issue 1, 2006, Pages 27-39

  Honrado, Emiliano ^a   Benítez, Javier ^a   Palacios, José ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

BRCA1; BRCA2; Hereditary breast cancer; Histopathology; Immunohistochemistry; Molecular pathology

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CADHERIN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN PRECURSOR;

APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; CELL CYCLE; CLINICAL FEATURE; GENE FREQUENCY; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GERM LINE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDULLARY CARCINOMA; MORPHOLOGY; MYOEPITHELIUM CELL; NONHUMAN; OVARY CANCER; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE DETECTION; HUMANS; MUTATION; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 33745142240     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.01.006     Document Type: Review

References (110)

1. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (1998) 676-689
2. Ottini L., Masala G., D'Amico C., et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 63 (2003) 342-347
3. Shih H.A., Couch F.J., Nathanson K.L., et al. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 20 (2002) 994-999
4. Stratton M.R., Ford D., Neuhasen S., et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 7 (1994) 103-107
5. Hakansson S., Johannsson O., Johansson U., et al. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet 60 (1997) 1068-1078
6. Serova O.M., Mazoyer S., Puget N., et al. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?. Am J Hum Genet 60 (1997) 486-495
7. Meindl A. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97 (2002) 472-480
8. van Beers E.H., van Welsem T., Wessels L.F., et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 65 (2005) 822-827
9. Osorio A., Barroso A., Martinez B., et al. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82 (2000) 1266-1270
10. Diez O., Osorio A., Duran M., et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22 (2003) 301-312
11. Lakhani S.R., van de Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 (2002) 2310-2318
12. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 (1998) 1138-1145
13. Lakhani S.R., Easton D.F., and Stratton M.R. Consortium tBCL. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349 (1997) 1505-1510
14. Armes J.E., Egan A.J., Southey M.C., et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83 (1998) 2335-2345
15. Lakhani S.R. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1 (1999) 31-35
16. Marcus J.N., Watson P., Page D.L., and Lynch H.T. Pathology and heredity of breast cancer in younger women. J Natl Cancer Inst Monogr (1994) 23-34
17. Marcus J.N., Watson P., Page D.L., et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 44 (1997) 275-277
18. Johannsson O.T., Idvall I., Anderson C., et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33 (1997) 362-371
19. Armes J.E., Trute L., White D., et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59 (1999) 2011-2017
20. Lynch B.J., Holden J.A., Buys S.S., Neuhausen S.L., and Gaffney D.K. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 29 (1998) 1140-1144
21. Agnarsson B.A., Jonasson J.G., Bjornsdottir I.B., Barkardottir R.B., Egilsson V., and Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 47 (1998) 121-127
22. Foulkes W.D., Stefansson I.M., Chappuis P.O., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95 (2003) 1482-1485
23. Foulkes W.D., Brunet J.S., Stefansson I.M., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64 (2004) 830-835
24. Palacios J., Honrado E., Osorio A., et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90 (2005) 5-14
25. Palacios J., Honrado E., Osorio A., Diez O., Rivas C., and Benitez J. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96 (2004) 712-714
26. Verhoog L.C., Brekelmans C.T., Seynaeve C., et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17 (1999) 3396-3402
27. Loman N., Johannsson O., Bendahl P.O., Borg A., Ferno M., and Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83 (1998) 310-319
28. Karp S.E., Tonin P.N., Begin L.R., et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80 (1997) 435-441
29. Noguchi S., Kasugai T., Miki Y., Fukutomi T., Emi M., and Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85 (1999) 2200-2205
30. Phillips K.A. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18 (2000) 107S-112S
31. Lakhani S.R., Gusterson B.A., Jacquemier J., et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6 (2000) 782-789
32. Palacios J., Honrado E., Osorio A., et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9 (2003) 3606-3614
33. Eerola H., Heikkila P., Tamminen A., Aittomaki K., Blomqvist C., and Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7 (2005) R93-R100
34. Ridolfi R.L., Rosen P.P., Port A., Kinne D., and Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 40 (1977) 1365-1385
35. Rubens J.R., Lewandrowski K.B., Kopans D.B., Koerner F.C., Hall D.A., and McCarthy K.A. Medullary carcinoma of the breast. Overdiagnosis of a prognostically favorable neoplasm. Arch Surg 125 (1990) 601-604
36. Rapin V., Contesso G., Mouriesse H., et al. Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61 (1988) 2503-2510
37. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
38. Garne J.P., Aspegren K., Linell F., Rank F., and Ranstam J. Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade. Cancer 73 (1994) 1438-1448
39. Henson D.E., Ries L., Freedman L.S., and Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 68 (1991) 2142-2149
40. Eisinger F., Nogues C., Guinebretiere J.M., et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 84 (1999) 263-267
41. Chappuis P.O., Nethercot V., and Foulkes W.D. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18 (2000) 287-295
42. Foulkes W.D., Metcalfe K., Sun P., et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10 (2004) 2029-2034
43. Robson M.E., Chappuis P.O., Satagopan J., et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6 (2004) R8-R17
44. Osin P., Gusterson B.A., Philp E., et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 34 (1998) 1683-1686
45. Osin P.P., and Lakhani S.R. The pathology of familial breast cancer: immunohistochemistry and molecular analysis. Breast Cancer Res 1 (1999) 36-40
46. Eerola H., Heikkila P., Tamminen A., Aittomaki K., Blomqvist C., and Nevanlinna H. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7 (2005) R465-R469
47. Vaziri S.A., Krumroy L.M., Elson P., et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7 (2001) 1937-1945
48. MacLachlan T.K., Dash B.C., Dicker D.T., and El-Deiry W.S. Repression of BRCA1 through a feedback loop involving p53. J Biol Chem 275 (2000) 31869-31875
49. Xu B., Kim S., and Kastan M.B. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 21 (2001) 3445-3450
50. Harkin D.P., Bean J.M., Miklos D., et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97 (1999) 575-586
51. Pao G.M., Janknecht R., Ruffner H., Hunter T., and Verma I.M. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97 (2000) 1020-1025
52. Brodie S.G., and Deng C.X. BRCA1-associated tumorigenesis: what have we learned from knockout mice?. Trends Genet 17 (2001) S18-S22
53. Crook T., Brooks L.A., Crossland S., et al. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17 (1998) 1681-1689
54. Phillips K.A., Nichol K., Ozcelik H., et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 91 (1999) 469-473
55. Greenblatt M.S., Chappuis P.O., Bond J.P., Hamel N., and Foulkes W.D. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61 (2001) 4092-4097
56. Gasco M., Yulug I.G., and Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat 21 (2003) 301-306
57. Owens M.A., Horten B.C., and Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5 (2004) 63-69
58. Lebeau A., Deimling D., Kaltz C., et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19 (2001) 354-363
59. Grushko T.A., Blackwood M.A., Schumm P.L., et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62 (2002) 1481-1488
60. Adem C., Soderberg C.L., Hafner K., et al. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 41 (2004) 1-11
61. Krajewski S., Krajewska M., Turner B.C., et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 6 (1999) 29-40
62. Freneaux P., Stoppa-Lyonnet D., Mouret E., et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 83 (2000) 1318-1322
63. Hadjiloucas I., Gilmore A.P., Bundred N.J., and Streuli C.H. Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase 3: relation to tumour histopathological characteristics. Br J Cancer 85 (2001) 1522-1526
64. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103-112
65. Gillett C.E., Lee A.H., Millis R.R., and Barnes D.M. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 184 (1998) 396-400
66. Gillett C., Smith P., Gregory W., et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69 (1996) 92-99
67. Frierson Jr. H.F., Gaffey M.J., Zukerberg L.R., Arnold A., and Williams M.E. Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Mod Pathol 9 (1996) 725-730
68. Vaziri S.A., Tubbs R.R., Darlington G., and Casey G. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 54 (2001) 259-263
69. Chappuis P.O., Donato E., Goffin J.R., et al. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 16 (2005) 735-742
70. Schraml P., Bucher C., Bissig H., et al. Cyclin E overexpression and amplification in human tumours. J Pathol 200 (2003) 375-382
71. Grushko T.A., Dignam J.J., Das S., et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10 (2004) 499-507
72. Kauraniemi P., Hedenfalk I., Persson K., et al. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res 60 (2000) 5323-5328
73. Palacios J., Benito N., Pizarro A., et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am J Pathol 146 (1995) 605-612
74. van de Rijn M., Perou C.M., Tibshirani R., et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161 (2002) 1991-1996
75. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
76. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003) 8418-8423
77. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
78. Arnes J.B., Brunet J.S., Stefansson I., et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11 (2005) 4003-4011
79. Korsching E., Packeisen J., Agelopoulos K., et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82 (2002) 1525-1533
80. Marcus J.N., Watson P., Page D.L., et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77 (1996) 697-709
81. Gretarsdottir S., Thorlacius S., Valgardsdottir R., et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 58 (1998) 859-862
82. Baekelandt M., Holm R., Nesland J.M., Trope C.G., and Kristensen G.B. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol 18 (2000) 3775-3781
83. Schuyer M., van der Burg M.E., Henzen-Logmans S.C., et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85 (2001) 1359-1367
84. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 (2001) 539-548
85. Chappuis P.O., Kapusta L., Begin L.R., et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18 (2000) 4045-4052
86. Wessels L.F., van Welsem T., Hart A.A., van't Veer L.J., Reinders M.J., and Nederlof P.M. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62 (2002) 7110-7117
87. Tirkkonen M., Johannsson O., Agnarsson B.A., et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57 (1997) 1222-1227
88. Kainu T., Juo S.H., Desper R., et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 97 (2000) 9603-9608
89. Alvarez S., Diaz-Uriarte R., Osorio A., et al. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res 11 (2005) 1146-1153
90. Maguire P., Holmberg K., Kost-Alimova M., Imreh S., Skoog L., and Lindblom A. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12. Int J Mol Med 16 (2005) 135-141
91. Jonsson G., Naylor T.L., Vallon-Christersson J., et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65 (2005) 7612-7621
92. Hoogerbrugge N., Bult P., de Widt-Levert L.M., et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21 (2003) 41-45
93. Kauff N.D., Brogi E., Scheuer L., et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97 (2003) 1601-1608
94. Hermsen B.B., von Mensdorff-Pouilly S., Fabry H.F., et al. Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer. J Pathol 206 (2005) 220-223
95. Adem C., Reynolds C., Soderberg C.L., et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97 (2003) 1-11
96. Jacquemier J., Eisinger F., Guinebretiere J.M., Stoppa-Lyonnet D., and Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet 348 (1996) 1098
97. Sun C.C., Lenoir G., Lynch H., and Narod S.A. In-situ breast cancer and BRCA1. Lancet 348 (1996) 408
98. Claus E.B., Petruzella S., Matloff E., and Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293 (2005) 964-969
99. King T.A., Gemignani M.L., Li W., et al. Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Res 64 (2004) 5051-5053
100. Futreal P.A., Liu Q., Shattuck-Eidens D., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (1994) 120-122
101. Staff S., Isola J.J., Johannsson O., Borg A., and Tanner M.M. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa. Br J Cancer 85 (2001) 1201-1205
102. Osorio A., de la Hoya M., Rodriguez-Lopez R., et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 99 (2002) 305-309
103. Lakhani S.R., Chaggar R., Davies S., et al. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol 189 (1999) 496-503
104. Cavalli L.R., Singh B., Isaacs C., Dickson R.B., and Haddad B.R. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Genet Cytogenet 149 (2004) 38-43
105. Isaacs C., Cavalli L.R., Cohen Y., et al. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from high-risk patients. Breast Cancer Res Treat 84 (2004) 99-105
106. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11 (2005) 5175-5180
107. D'Andrea A.D., and Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3 (2003) 23-34
108. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., and Harkin D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96 (2004) 1659-1668
109. van der Groep P., Bouter A., van der Zanden R., et al. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96 (2004) 712-713 [author reply 4]
110. Cortes-Funes H., and Soto Parra H. Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer 89 Suppl. 2 (2003) S3-S8